15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Tenax Therapeutics Inc, 3 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $4.00 to $50.00 (about 12.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $17.17 sits 765% above the current $1.99. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy343%
Hold457%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Tenax Therapeutics Inc.
As of Sep, 3 of 7 firms rate TENX a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TENX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.43 – $-0.34 · 7 analysts · +0% YoY
Next period, 7 analysts expect Tenax Therapeutics Inc to earn $-0.38 a share (range $-0.43 – $-0.34), versus $-0.38 a year earlier. Full-year consensus is $-1.45, growing to $-1.50 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tenax Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TENX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$50.00+2418.9% to target
Overall win rate
33%
+ Follow
#2
WI
Whitney Ijem
Canaccord Genuity · Rank #350
Buy
$35.00+1663.2% to target
Overall win rate
32%
+ Follow
#3
Jonathan Aschoff
Roth MKM · Rank #453
Buy
$5.00+151.9% to target
Overall win rate
28%
+ Follow
#4
Seamus Fernandez
Guggenheim
Hold
No targeton TENX
Coverage
—
+ Follow
#5
David Risinger
Leerink Partners
Buy
$4.00+101.5% to target
Coverage
—
+ Follow
TENX stock forecast FAQ
What is TENX's average 12-month price target?+
The 5 analysts with a live target average $17.17 for Tenax Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $4.00 low.
Is TENX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 3 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TENX?+
The Street-high target is $50.00 (Piper Sandler), and the Street-low is $4.00 (Canaccord Genuity). The average of all 5 active targets is $17.17.
How many Wall Street analysts cover TENX?+
7 analysts have an active rating on Tenax Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TENX?+
Among analysts who currently cover TENX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #188). Their current call is Buy with a $50.00 target.
What is Tenax Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.43 – $-0.34) across 7 analysts. Full-year EPS is projected at $-1.45, rising to $-1.50 the following year.
How much revenue is Tenax Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TENX lately?+
As of Sep, 3 of 7 firms rate TENX a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TENX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Chardan Capital
Canaccord Genuity
